Frontier Medicines to Present Preclinical Data for FMC-242, a Novel Covalent Allosteric PI3Kα-RAS Breaker, at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

November 4, 2026